Alzamend Neuro, Inc.

Q: Jul 31 2026

FY: Apr 30 2026

Q: Jan 31 2026

Q: Oct 31 2025

Q: Jul 31 2025

FY: Apr 30 2025

Q: Jan 31 2025

Q: Oct 31 2024

Q: Jul 31 2024

FY: Apr 30 2024

FY: Apr 30 2024

Q: Jan 31 2024

Q: Jan 31 2024

Q: Oct 31 2023

Q: Jul 31 2023

FY: Apr 30 2023

Q: Jan 31 2023

Q: Oct 31 2022

Q: Jul 31 2022

FY: Apr 30 2022

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Other Events

Submission of Matters to a Vote of Security Holders

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Entry into a Material Definitive Agreement

Other Events

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Unregistered Sales of Equity Securities

Unregistered Sales of Equity Securities

Unregistered Sales of Equity Securities

Results of Operations and Financial Condition

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Submission of Matters to a Vote of Security Holders

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Regulation FD Disclosure

1.01,9.01

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Amended Initial Registration Statement

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Amended Initial Registration Statement

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement with Pricing Information

Notice of Effectiveness

Preliminary Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

AULT MILTON C III

AULT MILTON C III

AULT MILTON C III

Hyperscale Data, Inc.; Ault Lending, LLC; Ault Capital Group, Inc.

Hyperscale Data, Inc.; Ault Lending, LLC; Ault Capital Group, Inc.

Hyperscale Data, Inc.

Katzoff David J

Jackman Stephan

GUSTAFSON MARK

Oram Jeffrey

Horne William B.

AULT MILTON C III

Nisser Henry Carl

AULT MILTON C III

Hyperscale Data, Inc.

AULT MILTON C III

AULT MILTON C III

Horne William B.

McGrath Lynne Fahey

AULT MILTON C III

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC